Bruce Levine, PhD University of Pennsylvania Philadelphia, PA, United States
[1] Caplan A, Levine B. Hope, Hype and Help: Ethically Assessing the Growing Market in Stem Cell Therapies. Am J Bioeth 2010;10(5):24-25.
[2] Gunter KC, Caplan AL, Mason C, Salzman R, Janssen WE, Nichols K, Bouzas LF, Lanza F, Levine BL, Rasko JEJ, Shimosaka A, Horwitz E. Cell therapy medical tourism: Time for action. Cytotherapy 2010;12(8):965-968.
[3] Dominici M, Nichols K, Srivastava A, Weiss DJ, Eldridge P, Cuende N, Deans RJ, Rasko JEJ, Levine AD, Turner L, Griffin DL, O’Donnell L, Forte M, Mason C, Wagena E, Janssen W, Nordon R, Wall D, Ho HN, Ruiz MA, Wilton S, Horwitz EM, Gunter KC. Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective. Cytotherapy 2015;17(12):1663-1666.
[4] Khoury M, Ikonomou L, Dominici M, LeBlanc K, Levine BL, Weiss DJ. The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products? Stem Cells Dev 2021;30(3):119-127.
[5] Cuende N, Ciccocioppo R, Forte M, Galipeau J, Ikonomou L, Levine BL, Srivastava A, Zettler PJ. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. Cytotherapy 2022; In Press.
[6] Levine BL, Munsie M, Levine AD, Ikonomou L, International Society for C, Gene Therapy Committee on the Ethics of C, Gene T. The peril of the promise of speculative cell banking: Statement from the ISCT Committee on the Ethics of Cell and Gene Therapy. Cytotherapy 2022; In Press.
